Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China, Finland To Set Up Pharmaceutical Industry Fund

This article was originally published in PharmAsia News

Executive Summary

Finland and China investors will jointly set up a €30 million industry fund that exclusively invests in early-stage development of China's biopharmaceutical projects and supports their internationalization. Finnish Industry Investment Ltd., part of Finland's Ministry of Trade and Industry, will assume most of the country's €15 million investment with private capital making up the rest. Three Chinese private investors are in discussions and the Finns hope to secure government interest as well. The fund is also part of Finland's biotech health project that seeks collaboration with China's universities in R&D and offers services for Chinese products entering Europe. However, analysts point out that no proper exit strategy is in place, which could deter investors' participation. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel